Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA ® at the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people with the disease, will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) taking place November 2-4, 2023 in Phoenix, Arizona. Presentations will highlight results from two open-label extension studies demonstrating the long-term clinical benefits and safety profile of TRIKAFTA® among CF pediatric populations.
Vertex will present interim data on TRIKAFTA® from its longest pediatric follow-up study to date. This interim analysis through Week 144 of a 192-week open-label extension study of TRIKAFTA® in children 6 years of age and older with CF and at least one F508del allele showed sustained improvements in CFTR function and respiratory symptoms following the pivotal study. In addition, there was no evidence of a decline in lung function during the treatment period of 3.5 years in the pivotal and extension studies. The data also showed a continued favorable safety profile, with no new safety findings (Poster #133).
In addition, 48-week interim results from a 192-week open-label study of TRIKAFTA® in children 2 years of age and older with cystic fibrosis and at least one F508del allele showed that the clinical benefits from the parent pivotal study were sustained, including improvements in lung function and CFTR function. There was also evidence suggesting continued improvement in exocrine pancreatic function with ongoing use of TRIKAFTA®. TRIKAFTA® continued to be generally safe and well tolerated through an additional 48 weeks of treatment (Poster #137).
“TRIKAFTA has fundamentally changed the course of CF treatment, and the data presented at this year’s NACFC is further evidence of the long-term benefits it brings to children with this disease,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We remain committed to developingmedicines that can be given to people with CF as young as possible, because we now know treating the disease early in life can slow disease progression.”
About Cystic Fibrosis
Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 88,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving.
About TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
INDICATIONS AND USAGE
TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or another mutation that is responsive to treatment with TRIKAFTA. Patients should talk to their doctor to learn if they have an indicated CF gene mutation. It is not known if TRIKAFTA is safe and effective in children under 2 years of age.
IMPORTANT SAFETY INFORMATION
Before taking TRIKAFTA, patients should tell their doctor about all of their medical conditions, including if they: are allergic to TRIKAFTA or any ingredients in TRIKAFTA, have kidney problems,have or have had liver problems, are pregnant or plan to become pregnant because it is not known if TRIKAFTA will harm an unborn baby, or are breastfeeding or planning to breastfeed because it is not known if TRIKAFTA passes into breast milk.
Patients should tell their doctor about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRIKAFTA may affect the way other medicines work, and other medicines may affect how TRIKAFTA works.The dose of TRIKAFTA may need to be adjusted when taken with certain medicines. Patients should ask their doctor or pharmacist for a list of these medicines if they are not sure. Patients should especially tell their doctor if they take: antibiotics such as rifampin or rifabutin; seizure medicines such as phenobarbital, carbamazepine, or phenytoin; St. John’s wort; antifungal medicines including ketoconazole, itraconazole, posaconazole, voriconazole, or fluconazole; antibiotics including telithromycin, clarithromycin, or erythromycin.
Patients should avoid food or drink that contains grapefruit while taking TRIKAFTA.
TRIKAFTA can cause serious side effects, including:
Liver damage and worsening of liver function in patients with severe liver disease that can be serious and may require transplantation. Liver damage has also happened in patients without liver disease.
High liver enzymes in the blood, which is a common side effect in patients treated with TRIKAFTA. These can be serious and may be a sign of liver injury. The patient’s doctor will do blood tests to check their liver before they start TRIKAFTA, every 3 months during the first year of taking TRIKAFTA, and every year while taking TRIKAFTA. Patients should call their doctor right away if they have any of the following symptoms of liver problems: pain or discomfort in the upper right stomach (abdominal) area; yellowing of the skin or the white part of the eyes; loss of appetite; nausea or vomiting; dark, amber-colored urine.
Serious allergic reactions have happened to patients who are treated with TRIKAFTA. Call your healthcare provider or go to the emergency room right away if you have any symptoms of an allergic reaction. Symptoms of an allergic reaction may include: rash or hives; tightness of the chest or throat or difficulty breathing; swelling of the face, lips and/or tongue; difficulty swallowing; and light-headedness or dizziness.
Abnormality of the eye lens (cataract) has been noted in some children and adolescents treated with TRIKAFTA. If the patient is a child or adolescent, their doctor should perform eye examinations before and during treatment with TRIKAFTA to look for cataracts.
The most common side effects of TRIKAFTA include headache, upper respiratory tract infection (common cold) including stuffy and runny nose, stomach (abdominal) pain, diarrhea, rash, increase in liver enzymes, increase in a certain blood enzyme called creatine phosphokinase, flu (influenza), inflamed sinuses, and increase in blood bilirubin.
Patients should tell their doctor if they have any side effect that bothers them or that does not go away. These are not all the possible side effects of TRIKAFTA.For more information, patients should ask their doctor or pharmacist.
Please click here to see the full U.S. Prescribing Information for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor).
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes and alpha-1 antitrypsin deficiency.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Carmen Bozic, M.D., in this press release, and our plans to present data on TRIKAFTA® at the NACFC, including long-term clinical benefits and safety profile in CF pediatric populations. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's research and development programs may not support registration or further development of its compounds due to safety, efficacy, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kenvue to Participate in the Morgan Stanley Global Consumer & Retail Conference on December 6, 202328.11.2023 14:00:00 CET | Press release
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Morgan Stanley’s Global Consumer & Retail Conference, in New York. Chief Executive Officer and Director, Thibaut Mongon, and Chief Financial Officer, Paul Ruh, will participate in a fireside chat on Wednesday, December 6, 2023 at 11:45 a.m. Eastern Time. A live webcast of the session will be available at https://investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power
Bacardi Gifting Celebrates Sustainability Landmark28.11.2023 14:00:00 CET | Press release
Family-owned Bacardi has announced that it is not only cutting single-use plastic from its gift packs, it will also now reduce the number of cardboard gift boxes for some of its iconic brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128855110/en/ The new limited-edition label for Bacardi-owned BOMBAY SAPPHIRE eliminates the need for a gift pack. The striking design was inspired by the gin brand’s 100% sustainably sourced botanicals. (Photo: Business Wire) Four years ago, Bacardi set itself the ambitious goal of removing 100% of the single-use plastic from its gifting range by the end of 2023. Thanks to innovative new designs, the company has successfully removed almost 275 tons of single-use plastic used annually. “We are incredibly proud of what we have achieved to date but we want to go one step further,” said Rodolfo Nervi, Vice President Safety, Quality and Sustainability for Bacardi. “We don’t want to just red
New Research: 97% of U.S. CIOs Identify Cybersecurity as a Current Major Threat to Their Organization28.11.2023 14:00:00 CET | Press release
According to new research released by Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and SmartOut of Bandmanagement solutions, a staggering 97% of U.S.-based CIOs surveyed expressed serious concerns about at least one cybersecurity threat. This comprehensive survey encompassed responses from 502 CIOs and 510 network engineers in the U.S., U.K., France, Germany, and Australia. The primary cybersecurity concerns highlighted in the research included malware (42%), spam and phishing (34%), social engineering (31%), and insider threats (30%). Remarkably, malware also emerged as a significant threat for 42% of the surveyed network engineers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128568826/en/ New Research: 97% of U.S. CIOs Identify Cybersecurity as a Current Major Threat to Their Organization (Photo: Business Wire) While only 23% of U.S. CIOs reported distributed denial-of-se
New VCMI Guidance Opens Door for Corporate Carbon Credit Claims28.11.2023 11:36:00 CET | Press release
The Voluntary Carbon Markets Integrity Initiative (VCMI) has today released additional guidance for its Claims Code of Practice (Claims Code), enabling companies to make claims about their use of high-quality carbon credits. This guidance includes a Monitoring, Reporting and Assurance (MRA) Framework, a brand and associated mark for making ‘Carbon Integrity' Claims, and a beta version of an additional claim. Using the MRA framework and the ‘Carbon Integrity’ Claims branding, companies can now make Silver, Gold or Platinum Claims as outlined in the original Claims Code of Practice released in June. This means these companies can now make claims using high-quality carbon credits, directing finance to initiatives that mitigate climate change, and demonstrating that they are going above and beyond science-aligned emissions cuts. VCMI has also launched the beta version of a new claim – called the ‘Scope 3 Flexibility’ Claim - as a practical step to accelerate corporate climate action. Once
inDrive welcomes Stephen Kruger as Chief Technology and Product Officer28.11.2023 10:00:00 CET | Press release
inDrive, a global mobility and urban services platform, announces the appointment of Stephen Kruger as its Chief Technology and Product Officer. Stephen will be responsible for implementing inDrive’s technology and product development strategies as the company continues to expand into new geographies and business verticals. inDrive has built out its platform with geography-specific freight and courier offerings, as well as handyman services, in addition to its core ride-hailing business. The combined technology and product team is tasked with continuing to scale inDrive’s platform, implementing new product features to support growth and further diversification of the business. Welcoming Stephen to the team, inDrive founder and CEO Arsen Tomsky said: "Stephen's remarkable background in technology leadership aligns seamlessly with our vision for inDrive's future. His proven ability to drive organizational change and innovation will undoubtedly strengthen our position in the industry whil